Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

IGC Pharma (IGC) Gross Margin (2016 - 2025)

IGC Pharma (IGC) has disclosed Gross Margin for 16 consecutive years, with 51.83% as the latest value for Q3 2025.

  • Quarterly Gross Margin rose 377.0% to 51.83% in Q3 2025 from the year-ago period, while the trailing twelve-month figure was 46.2% through Sep 2025, down 1001.0% year-over-year, with the annual reading at 48.7% for FY2025, 580.0% down from the prior year.
  • Gross Margin for Q3 2025 was 51.83% at IGC Pharma, up from 46.95% in the prior quarter.
  • The five-year high for Gross Margin was 67.86% in Q3 2021, with the low at 30.72% in Q4 2022.
  • Average Gross Margin over 5 years is 50.51%, with a median of 48.06% recorded in 2024.
  • The sharpest move saw Gross Margin surged 4706bps in 2021, then plummeted -2473bps in 2024.
  • Over 5 years, Gross Margin stood at 43.66% in 2021, then fell by -30bps to 30.72% in 2022, then skyrocketed by 112bps to 65.2% in 2023, then plummeted by -38bps to 40.47% in 2024, then grew by 28bps to 51.83% in 2025.
  • According to Business Quant data, Gross Margin over the past three periods came in at 51.83%, 46.95%, and 46.67% for Q3 2025, Q2 2025, and Q1 2025 respectively.